electroCore, Inc.
NASDAQ:ECOR

Watchlist Manager
electroCore, Inc. Logo
electroCore, Inc.
NASDAQ:ECOR
Watchlist
Price: 16.0277 USD -1.43%
Market Cap: 105m USD
Have any thoughts about
electroCore, Inc.?
Write Note

electroCore, Inc.
Net Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

electroCore, Inc.
Net Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income CAGR 3Y CAGR 5Y CAGR 10Y
electroCore, Inc.
NASDAQ:ECOR
Net Income
-$12.7m
CAGR 3-Years
12%
CAGR 5-Years
25%
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Net Income
$1.7B
CAGR 3-Years
-6%
CAGR 5-Years
7%
CAGR 10-Years
4%
Boston Scientific Corp
NYSE:BSX
Net Income
$1.8B
CAGR 3-Years
24%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Stryker Corp
NYSE:SYK
Net Income
$3.6B
CAGR 3-Years
24%
CAGR 5-Years
1%
CAGR 10-Years
19%
Abbott Laboratories
NYSE:ABT
Net Income
$5.8B
CAGR 3-Years
-7%
CAGR 5-Years
12%
CAGR 10-Years
11%
Intuitive Surgical Inc
NASDAQ:ISRG
Net Income
$2.3B
CAGR 3-Years
10%
CAGR 5-Years
12%
CAGR 10-Years
18%
No Stocks Found

electroCore, Inc.
Glance View

Market Cap
104.3m USD
Industry
Health Care

electroCore, Inc. engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. The company is headquartered in Rockaway, New Jersey and currently employs 52 full-time employees. The company went IPO on 2018-06-22. nVNS is a platform for bioelectronic medical therapy that modulates neurotransmitters and immune function through its effects on both the peripheral and central nervous systems. The firm is providing gammaCore device for the treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults. gammaCore permits patients to self-administer doses of nVNS on an as-needed basis for treatment of prevent multiple types of headache pain via the vagus nerve. The gammaCore therapy is also used to treat primary headache, including migraine, cluster headache (CH), hemicrania continua and paroxysmal hemicrania (PH) and coronavirus (COVID-19).

ECOR Intrinsic Value
18.4922 USD
Undervaluation 13%
Intrinsic Value
Price

See Also

What is electroCore, Inc.'s Net Income?
Net Income
-12.7m USD

Based on the financial report for Sep 30, 2024, electroCore, Inc.'s Net Income amounts to -12.7m USD.

What is electroCore, Inc.'s Net Income growth rate?
Net Income CAGR 5Y
25%

Over the last year, the Net Income growth was 38%. The average annual Net Income growth rates for electroCore, Inc. have been 12% over the past three years , 25% over the past five years .

Back to Top